Table 6. Factors affecting adverse events occurrence by logistic regression model analysis.
| Parameters | Univariate logistic regression | Multivariate logistic regression | |||||||
|---|---|---|---|---|---|---|---|---|---|
| P value | OR | 95% CI | P value | OR | 95% CI | ||||
| Lower | Higher | Lower | Higher | ||||||
| DEB-TACE vs. cTACE | 0.507 | 1.167 | 0.739 | 1.843 | 0.012 | 3.740 | 1.344 | 10.403 | |
| Age ≥60 years | 0.371 | 0.804 | 0.499 | 1.297 | 0.570 | 0.744 | 0.269 | 2.063 | |
| Male | 0.877 | 0.948 | 0.480 | 1.871 | 0.919 | 1.092 | 0.201 | 5.921 | |
| History of drink | 0.038 | 0.581 | 0.348 | 0.970 | 0.513 | 0.701 | 0.241 | 2.035 | |
| History of HB | 0.887 | 0.966 | 0.599 | 1.557 | 0.826 | 1.129 | 0.384 | 3.316 | |
| History of HC | 0.497 | 0.577 | 0.118 | 2.823 | 1.000 | – | 0.000 | – | |
| History of cirrhosis | 0.067 | 1.541 | 0.970 | 2.446 | 0.416 | 0.637 | 0.215 | 1.890 | |
| Multifocal disease | 0.195 | 1.377 | 0.849 | 2.231 | 0.525 | 0.660 | 0.183 | 2.376 | |
| Tumor location-Bilobar | 0.175 | 1.385 | 0.865 | 2.216 | 0.018 | 6.469 | 1.385 | 30.219 | |
| Largest nodule size ≥7 cm | <0.001 | 3.312 | 2.036 | 5.387 | 0.066 | 2.896 | 0.932 | 8.996 | |
| Portal vein invasion | <0.001 | 0.326 | 0.197 | 0.538 | 0.916 | 0.911 | 0.161 | 5.154 | |
| Hepatic vein invasion | <0.001 | 0.187 | 0.097 | 0.359 | 0.899 | 1.122 | 0.190 | 6.617 | |
| Higher ECOG performance status | 0.224 | 0.751 | 0.474 | 1.191 | 0.750 | 0.836 | 0.279 | 2.509 | |
| Higher Child-Pugh stage | 0.147 | 1.467 | 0.874 | 2.461 | 0.225 | 0.412 | 0.098 | 1.727 | |
| Higher BCLC stage | <0.001 | 2.285 | 1.690 | 3.088 | 0.434 | 2.368 | 0.273 | 20.565 | |
| Previous cTACE treatment | <0.001 | 3.635 | 2.006 | 6.586 | <0.001 | 24.622 | 5.576 | 108.719 | |
| Previous surgery | 0.044 | 2.066 | 1.018 | 4.191 | 0.678 | 1.371 | 0.308 | 6.103 | |
| Previous systematic chemotherapy | 0.999 | – | 0.000 | – | 0.999 | 0.000 | 0.000 | – | |
| Previous radiofrequency ablation | 0.171 | 0.472 | 0.161 | 1.382 | 0.281 | 4.220 | 0.308 | 57.803 | |
| Previous targeted therapy | 0.457 | 0.602 | 0.158 | 2.289 | 0.999 | – | 0.000 | – | |
| ALT ≥1 ULN | 0.276 | 1.293 | 0.815 | 2.053 | 0.876 | 1.103 | 0.322 | 3.774 | |
| AST ≥1 ULN | 0.062 | 1.591 | 0.977 | 2.592 | 0.621 | 1.407 | 0.364 | 5.441 | |
| ALP ≥1 ULN | 0.040 | 1.675 | 1.024 | 2.740 | 0.993 | 1.005 | 0.310 | 3.256 | |
| TBIL ≥1 ULN | 0.142 | 1.419 | 0.890 | 2.264 | 0.522 | 1.581 | 0.390 | 6.415 | |
| ALB ≥1 ULN | 0.999 | 0.000 | 0.000 | – | 0.506 | 0.661 | 0.195 | 2.240 | |
| TP ≥1 ULN | 0.712 | 0.800 | 0.245 | 2.611 | 0.850 | 0.891 | 0.270 | 2.943 | |
| TBA ≥1 ULN | 0.598 | 0.881 | 0.551 | 1.409 | 0.309 | 0.543 | 0.167 | 1.761 | |
| WBC abnormal | 0.959 | 1.013 | 0.614 | 1.671 | 0.284 | 1.769 | 0.623 | 5.025 | |
| RBC abnormal | 0.584 | 0.879 | 0.555 | 1.393 | 0.416 | 0.649 | 0.228 | 1.842 | |
| ANC abnormal | 0.844 | 1.058 | 0.602 | 1.862 | 0.522 | 0.671 | 0.198 | 2.278 | |
| Hb abnormal | 0.163 | 1.393 | 0.874 | 2.219 | 0.620 | 1.357 | 0.405 | 4.548 | |
| PLT abnormal | 0.051 | 0.620 | 0.384 | 1.002 | 0.975 | 1.018 | 0.333 | 3.110 | |
| BCr abnormal | 0.423 | 1.469 | 0.573 | 3.767 | 0.866 | 1.158 | 0.211 | 6.362 | |
| BUN abnormal | 0.119 | 0.602 | 0.318 | 1.138 | 0.692 | 0.766 | 0.205 | 2.862 | |
| AFP abnormal | 0.052 | 1.697 | 0.994 | 2.896 | 0.990 | 1.007 | 0.361 | 2.811 | |
| CEA abnormal | 0.486 | 0.745 | 0.325 | 1.706 | 0.134 | 3.953 | 0.655 | 23.852 | |
| CA199 abnormal | 0.253 | 0.693 | 0.370 | 1.299 | 0.313 | 0.546 | 0.169 | 1.766 | |
Data were presented as P value, OR and 95% CI. Factors affecting adverse events occurrence were determined by univariate and multivariate logistic regression analysis. P value <0.05 was considered significant, and the significant results were shown in boldface. “–” indicated that the value was unable to be calculated due to lack of events. Child-pugh Stage was scored as 0-A, 1-B, 2-C; BCLC stage was scored as 1-Stage A, 2-Stage B, 3-Stage C, 4-Stage D, the logistic analysis was performed based on these definitions. OR, odds ratio; CI, confidence interval; DEB-TACE, drug-eluting bead transarterial chemoembolization; cTACE, conventional transarterial chemo-embolization; HB, hepatitis b; HC, hepatitis c; ECOG, Eastern Cooperative Oncology Group; BCLC, Barcelona Clinic Liver Cancer; ULN, upper limit of normal; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; TBIL, total bilirubin; ALB, albumin; TP, total protein; TBA, total bile acid; WBC, white blood cell; RBC, red blood cell; ANC, absolute neutrophil count; Hb, hemoglobin; PLT, platelet; BCr, blood creatinine; BUN, blood urea nitrogen; AFP, alpha fetoprotein; CEA, carcino-embryonic antigen; CA199, carbohydrate antigen 199.